33 related articles for article (PubMed ID: 33526918)
21. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
[TBL] [Abstract][Full Text] [Related]
22. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
Li JM; Giver CR; Lu Y; Hossain MS; Akhtari M; Waller EK
Immunotherapy; 2009 Jul; 1(4):599-621. PubMed ID: 20191089
[TBL] [Abstract][Full Text] [Related]
23. Predictors of hematologic malignancy relapse in patients with advanced chronic graft-versus-host disease.
Ruben CL; Pirsl F; Steinberg SM; Holtzman NG; Parsons-Wandell L; Baruffaldi J; Curtis LM; Mitchell SA; Kerep AZ; Cowen EW; Berger A; Joe GO; Datiles MB; Mays JW; Pavletic SZ
Bone Marrow Transplant; 2021 Jul; 56(7):1584-1592. PubMed ID: 33526918
[TBL] [Abstract][Full Text] [Related]
24. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.
Pavletic SZ; Kumar S; Mohty M; de Lima M; Foran JM; Pasquini M; Zhang MJ; Giralt S; Bishop MR; Weisdorf D
Biol Blood Marrow Transplant; 2010 Jul; 16(7):871-90. PubMed ID: 20399876
[TBL] [Abstract][Full Text] [Related]
25. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
26. Effect of pre-transplantation serum ferritin on outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation: A meta-analysis.
Yan Z; Chen X; Wang H; Chen Y; Chen L; Wu P; Wang W
Medicine (Baltimore); 2018 Jul; 97(27):e10310. PubMed ID: 29979374
[TBL] [Abstract][Full Text] [Related]
27. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.
Ijaz A; Khan AY; Malik SU; Faridi W; Fraz MA; Usman M; Tariq MJ; Durer S; Durer C; Russ A; Parr NNC; Baig Z; Sagar F; Ali Z; McBride A; Anwer F
Biol Blood Marrow Transplant; 2019 Jan; 25(1):94-99. PubMed ID: 30195074
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcomes of antithymocyte globulin in patients with hematological malignancies undergoing myeloablative allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
Du K; Hu Y; Wu K; Huang H
Clin Transplant; 2013; 27(2):E91-E100. PubMed ID: 23383989
[TBL] [Abstract][Full Text] [Related]
29.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
30.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
31.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
